
Will Ozempic Prices Increase? Novo Nordisk’s Tariff Concerns
Novo Nordisk is witnessing soaring sales for its diabetes and weight-loss drugs, particularly Ozempic and Wegovy, with total revenues reaching approximately $32 billion. However, concerns about potential U.S. tariffs pose uncertainty. Despite this, CEO Lars Fruergaard Jørgensen remains optimistic, emphasizing strong market demand and strategic investments to address challenges in the evolving political landscape.








